Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7%
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower revenues and adjusted earnings for the fourth quarter of fiscal 2025. The...
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower revenues and adjusted earnings for the fourth quarter of fiscal 2025. The...
Roivant Sciences (Nasdaq: ROIV) reported its financial results for the fiscal third quarter ended December 31, 2025, underscored by positive...
Abbott (NYSE: ABT) on Friday reported positive data from studies evaluating the safety and effectiveness of its Volt Pulsed Field...
Roivant Sciences (Nasdaq: ROIV) on Friday reported its financial results for the fiscal third quarter ended December 31, 2025, revealing...